CN110066744A - 一株基因组重排高产菌及其在生产天赐霉素中的应用 - Google Patents
一株基因组重排高产菌及其在生产天赐霉素中的应用 Download PDFInfo
- Publication number
- CN110066744A CN110066744A CN201811453409.3A CN201811453409A CN110066744A CN 110066744 A CN110066744 A CN 110066744A CN 201811453409 A CN201811453409 A CN 201811453409A CN 110066744 A CN110066744 A CN 110066744A
- Authority
- CN
- China
- Prior art keywords
- bestowed
- heaven
- mycin
- tnm
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 title abstract description 10
- 238000000855 fermentation Methods 0.000 claims abstract description 15
- 230000004151 fermentation Effects 0.000 claims abstract description 15
- 230000008707 rearrangement Effects 0.000 claims abstract description 11
- 239000001963 growth medium Substances 0.000 claims description 16
- 239000011347 resin Substances 0.000 claims description 8
- 229920005989 resin Polymers 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- 101100313763 Arabidopsis thaliana TIM22-2 gene Proteins 0.000 claims description 5
- 229920000742 Cotton Polymers 0.000 claims description 5
- 239000002250 absorbent Substances 0.000 claims description 4
- 230000002745 absorbent Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 241000187180 Streptomyces sp. Species 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- 229910052927 chalcanthite Inorganic materials 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 229930182566 Gentamicin Natural products 0.000 abstract description 7
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 abstract description 7
- 229960002518 gentamicin Drugs 0.000 abstract description 7
- 229930014626 natural product Natural products 0.000 abstract description 5
- 241001655322 Streptomycetales Species 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 13
- 238000012216 screening Methods 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 7
- 239000008272 agar Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 210000001938 protoplast Anatomy 0.000 description 7
- 238000011218 seed culture Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 239000007195 tryptone soya broth Substances 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 239000013587 production medium Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 231100000350 mutagenesis Toxicity 0.000 description 5
- 238000002703 mutagenesis Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241000191938 Micrococcus luteus Species 0.000 description 4
- 239000001888 Peptone Substances 0.000 description 4
- 108010080698 Peptones Proteins 0.000 description 4
- 241001152205 Streptomyces sp. CB03234 Species 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 235000019319 peptone Nutrition 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- OBGWIHKWGGEOEV-WJPOXRCESA-N (1S,17S,20Z,24R,26R)-4,24-dihydroxy-26-[(1R)-1-hydroxyethyl]-25-oxa-16-azahexacyclo[15.7.2.01,26.02,15.05,14.07,12]hexacosa-2,4,7,9,11,14,20-heptaen-18,22-diyne-6,13-dione Chemical compound O[C@@H]1C#C\C=C/C#C[C@@H]2NC(C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C3)=C3[C@@]31O[C@]32[C@H](O)C OBGWIHKWGGEOEV-WJPOXRCESA-N 0.000 description 3
- 229930193152 Dynemicin Natural products 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 3
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 3
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- OBGWIHKWGGEOEV-UHFFFAOYSA-N uncialamycin Natural products OC1C#CC=CC#CC2NC(C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C3)=C3C31OC32C(O)C OBGWIHKWGGEOEV-UHFFFAOYSA-N 0.000 description 3
- DGGZCXUXASNDAC-QQNGCVSVSA-N C-1027 chromophore Chemical compound COc1cc2OC(=C)C(=O)Nc2c(c1)C(=O)O[C@H]3COC(=O)C[C@H](N)c4cc(O)c(O[C@@H]5C#C\C=C\3/C#CC6=CC=C[C@]56O[C@@H]7OC(C)(C)[C@H]([C@@H](O)[C@H]7O)N(C)C)c(Cl)c4 DGGZCXUXASNDAC-QQNGCVSVSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000007614 genetic variation Effects 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- WHWDWIHXSPCOKZ-UHFFFAOYSA-N hexahydrofarnesyl acetone Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)=O WHWDWIHXSPCOKZ-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 229960005535 lidamycin Drugs 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 229940124294 CD33 monoclonal antibody Drugs 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Chinese gallotannin Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 229930189413 Esperamicin Natural products 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
- 229930195731 calicheamicin Natural products 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229910052564 epsomite Inorganic materials 0.000 description 1
- LJQQFQHBKUKHIS-WJHRIEJJSA-N esperamicin Chemical compound O1CC(NC(C)C)C(OC)CC1OC1C(O)C(NOC2OC(C)C(SC)C(O)C2)C(C)OC1OC1C(\C2=C/CSSSC)=C(NC(=O)OC)C(=O)C(OC3OC(C)C(O)C(OC(=O)C=4C(=CC(OC)=C(OC)C=4)NC(=O)C(=C)OC)C3)C2(O)C#C\C=C/C#C1 LJQQFQHBKUKHIS-WJHRIEJJSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108010087005 glusulase Proteins 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229950004101 inotuzumab ozogamicin Drugs 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- RSXFZXJOBQZOOM-WXIIGEIKSA-N kedarcidin Chemical compound O([C@@H]\1COC(=O)C[C@H](C2=CC=C(C(=N2)Cl)O[C@@H]2[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@](C)(O)C3)[C@]34O[C@H]3C#C/C=C/1C#CC4=C2)NC(=O)C=1C(O)=CC2=CC(OC(C)C)=C(C(=C2C=1)OC)OC)[C@H]1C[C@H](O)[C@H](N(C)C)[C@H](C)O1 RSXFZXJOBQZOOM-WXIIGEIKSA-N 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/465—Streptomyces
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了一株基因组重排高产菌及其在生产天赐霉素中的应用,所述基因组重排高产菌为Streptomyces sp.CB03234‑GS26,已于2018年7月16日保藏在中国典型培养物保藏中心,保藏编号为CCTCC M 2018485。本发明通过基于已有高产菌株Streptomyces sp.CB03234‑S(保藏编号为CCTCC M 2017538)和庆大霉素抗性核糖体工程突变菌Streptomyces sp.CB03234‑G的基因组重排,获得稳定的新型烯二炔类天然产物天赐霉素‑A(TNM‑A)的高产菌株CB03234‑GS26,其TNM‑A的发酵产率超过38 mg/L。
Description
技术领域
本发明涉及一株基因组重排高产菌及其在生产天赐霉素中的应用,属于生物医药技术领域。
背景技术
烯二炔类天然产物具有独特的共轭炔-烯-炔分子结构和超强生物活性,是最具开发前景的一类抗肿瘤抗生素,根据其核心结构可分为包括新制癌菌素(neocarzinotatin,NCS)、力达霉素(C-1027)、kedarcidin和maduropepti等在内的九元环烯二炔,以及包括卡奇霉素(calicheamicin,CAL)、esperamicin、dynemicin(DYN)和uncialamycin(UCM)等在内的十元环烯二炔。烯二炔类抗肿瘤抗生素的生物活性主要依赖于其诱导的DNA损伤机制,即通过电子重排形成暂时性苯环双自由基,对DNA小沟进行亲核攻击后形成以脱氧核糖核酸碳链为中心的自由基,并在分子氧的作用下引起单链或双链DNA的断裂。作为迄今为止发现的细胞毒性最强的一类分子,烯二炔类天然产物可作为抗肿瘤抗体偶联药物(ADC)的弹头分子,具有极高的成药前景。目前发现的13种烯二炔分子中,NCS和CAL已被开发成为临床药物,其中由日本开发的SMANCS(聚苯乙烯马来酸共轭NCS)主要用于治疗肝癌,而美国辉瑞公司最近开发的ADC药物Mylotarg(CD33单克隆抗体偶联CAL)和Besponsa(CD22单克隆抗体偶联CAL)则分别用于治疗急性骨髓性白血病和成人复发或难治性B细胞前体急性淋性白血病。
天赐霉素-A(Tiancimycin-A,缩略TNM-A)是2016年通过基因组挖掘技术从链霉菌(Streptomyces sp.CB03234,简称CB03234)的发酵产物中分离发现的一种新型十元环烯二炔抗肿瘤抗生素,其结构如下所示:
结构式中右侧的十字交叉处没有碳原子。
天赐霉素-A与UCM和DYN结构类似,对多种恶性肿瘤细胞有超高的活性,超过目前临床一线化疗药物丝裂霉素近千倍,并且表现出更快速和更完整的肿瘤细胞杀伤力,将是抗肿瘤ADC药物理想的弹头药物分子,该成果已发表在国际微生物权威期刊MBio.上(2016;7(6).pii:e02104-16)。TNM-A在原始菌株(Streptomyces sp.CB03234)中的产量极低,仅为0.3mg/L左右,而目前达到工业化制备水平的其它烯二炔类天然产物的产量均在20mg/L以上,因此现有TNM-A的来源远远不能满足临床研究和工业化生产的应用需求。同时TNM-A因其复杂独特的分子结构,无法通过传统的化学合成方法来获取,通过微生物发酵是目前制备TNM-A最切实可行的手段。
基因组重排主要利用原生质体融合对微生物进行全基因组范围的片段重组和交换,经过多轮递推筛选融合子来不断地累积有益的突变,从而实现目标菌种的正向进化,与传统育种方法相比具有许多明显优势。基于核糖体工程对TNM-A原始产生菌株Streptomyces sp.CB03234进行突变,分别获得了具有不同抗生素抗性的突变菌株,其TNM-A的产量均比原始菌株有明显提高。在此基础上,以上述核糖体工程突变菌株为亲本,运用基于原生质体融合的基因组重排,筛选获得TNM-A产量进一步提升的高产菌株,将为实现其规模化生产和制备,推动TNM-A后继的抗癌活性分析、作用机理等临床前期研究,以及相关抗肿瘤ADC新药的开发奠定重要基础。
发明内容
本发明解决的技术问题是,提高TNM-A的产量,以满足工业化生产的应用需求。
本发明通过对活性极强的新型烯二炔类天然产物天赐霉素-A(TNM-A)的原始生产菌株Streptomyces sp.CB03234进行基于庆大霉素抗性的核糖体工程菌种诱变,筛选获得TNM-A的高产菌株CB03234-G,并基于已有TNM-A的高产菌株CB03234-S(发酵产率达到7mg/L左右,该菌株已于2017年9月25日保藏到中国典型培养物保藏中心,保藏编号为CCTCC M2017538),通过对CB03234-G和CB03234-S进行基于原生质体融合的基因组重排,最终筛选获得TNM-A高产菌株CB03234-GS26。
本发明的技术方案是,提供一株基因组重排高产突变菌,同样也属于链霉菌,所述链霉菌为Streptomyces sp.CB03234-GS26,已于2018年7月16日保藏在中国典型培养物保藏中心,保藏编号为CCTCC M 2018485。
本发明制备上述CB03234-GS26菌株的步骤如下:
1)链霉菌CB03234的庆大霉素抗性核糖体工程诱变;
2)链霉菌CB03234突变菌株生物活性高通量筛选及TNM-A高产菌株CB03234-G的获得;
3)将菌株CB03234-S与CB03234-G进行基因组重排获得TNM-A高产菌株CB03234-GS26。
所述链霉菌CB03234-GS26可应用在天赐霉素-A及其衍生物的制备,所述天赐霉素-A的结构式为:
利用上述链霉菌进行发酵制备天赐霉素-A,发酵过程中使用的培养基的组成如下:40g/L可溶性淀粉,20g/L棉籽粉,0.1g/L CuSO4·5H2O,0.005g/L NaI和2g/L CaCO3,培养基的pH为7.0,并在每升培养基中添加10g HP20大孔吸附树脂。
本发明通过核糖体工程诱变及高通量生物活性筛选获得稳定的TNM-A高产菌株CB03234-G,其TNM-A的发酵产率达到3.7mg/L左右,将菌株CB03234-S与CB03234-G进行基因组重排筛选获得TNM-A高产菌株CB03234-GS26,产量达到38mg/L左右。
保藏信息
菌种名称:链霉菌CB03234-GS26;菌种的拉丁文属名:Streptomyces sp.;保藏编号:CCTCC No.:M 2018485;保藏日期:2018年7月16日;保藏单位:中国典型培养物保藏中心;保藏单位地址:中国武汉,武汉大学。
具体实施方式
下面结合实施例进一步解释和说明本发明,如无特别说明,涉及洗脱液、流动相的百分数为体积百分数,其他的百分数为质量百分含量。
实施例1:链霉菌CB03234的培养和发酵及TNM-A的生物活性检测
将链霉菌CB03234接种至高氏1号(G1)固体培养基(所述G1固体培养基为:10g/L可溶性淀粉、0.5g/L MgSO4·7H2O、0.5g/L K2HPO4、1g/L NaCl、1g/L KNO3、0.01g/L FeSO4·7H2O、20g/L琼脂,pH=7.0)斜面上,在30℃恒温条件下培养8-15天左右,用无菌20%甘油溶液收集孢子获得孢子悬浮液后冷藏于-80℃备用。为获得目标产物TNM-A,将50μL CB03234孢子悬浮液接种至50mL胰蛋白胨大豆肉汤(TSB)种子培养基(所述TSB种子培养基为:17g/L胰蛋白胨、3g/L植物蛋白胨、2.5g/L K2HPO4、5g/L NaCl、2.5g/L葡萄糖,pH=7.3)中,在30℃和200rpm条件下培养48小时后,将5mL种子转接至含有50mL生产培养基(所述生产培养基为:10g/L可溶性淀粉、5g/L棉籽粉、2g/L CaCO3、0.05g/L CuSO4、0.005g/L NaI,并在每升培养基中添加10g HP20大孔吸附树脂)的250mL三角烧瓶中,在30℃和200rpm条件下培养7天。将所得发酵液离心后取上清液,以藤黄微球菌(Micrococcus luteus)ATCC10240为生物活性指示菌在标准LB培养基平板上进行纸片法测试(20μL发酵上清液/片),通过测量抑菌圈的大小来初步估算发酵液中TNM-A的含量。
实施例2:链霉菌CB03234的庆大霉素抗性核糖体工程诱变
将链霉菌CB03234接种至G1固体培养基斜面上,在30℃恒温条件下培养8-15天左右,用无菌20%甘油溶液收集孢子,所得孢子混合液经振荡打散后用无菌砂芯漏斗过滤,并通过平板稀疏涂布进行孢子计数,最终制成均一化浓度的孢子悬浮液。同时配制浓度为10mg/mL的庆大霉素(Gen)水溶液并进行过滤除菌,在此基础上配置含有不同浓度Gen的G1固体培养基平板;将CB03234的孢子悬浮液稀释50-100倍后取100μL与5mL含有不同浓度Gen的G1软琼脂培养基(培养基其它成分与G1相同,琼脂为10g/L)混合均匀后平铺至含对应浓度Gen的G1固体培养基平板上(每种Gen浓度平行培养3块平板),在30℃培养4-5天后观察菌落存活情况,最终确定Gen的最小抑菌浓度(MIC)为15mg/L。在上述研究基础上,选取4种不同的Gen浓度(15mg/L、20mg/L、40mg/L、60mg/L、80mg/L)进行链霉菌CB03234的核糖体工程诱变(表2)。每种浓度按照上述接种流程平行接种10块G1平板,在30℃恒温条件下培养7-8天后挑选存活的单菌落。
实施例3:链霉菌CB03234突变菌株生物活性高通量筛选
将挑选的CB03234及其相关突变菌株的单菌落分别平行接种至两块96孔板G1固体生长培养基中。将接种的96孔板于30℃恒温培养8-15天后,挑选对应单菌落的琼脂块,放置于打孔的LB平板上,以藤黄微球菌(Micrococcus luteus)ATCC10240为生物活性测试指示菌,将1mL ATCC10240菌液与4mL LB软琼脂培养基混合均匀后倾倒在置有待筛选单菌落琼脂块的LB平板上,待其凝固后于37℃恒温培养过夜,以原始菌株为参照,通过测量对应单菌落琼脂块的抑菌圈大小来快速筛选潜在的TNM-A高产菌株,最终从59个突变株中筛选出34株进行进一步的发酵验证(表2)。
表2.CB03234菌株的核糖体工程诱变及生物活性高通量筛选结果
Gen筛选浓度(mg/L) | 15 | 20 | 40 | 60 | 80 |
生长单菌落数 | 10 | 20 | 4 | 18 | 7 |
抑菌圈大于原始菌株数 | 3 | 9 | 0 | 17 | 5 |
实施例4:TNM-A高产菌株CB03234-G的确定
将抑菌圈大于原始菌株CB03234的突变单菌落,转接至50mL含有对应浓度Gen的胰蛋白胨大豆肉汤(TSB)种子培养基(所述TSB种子培养基为:17g/L胰蛋白胨、3g/L植物蛋白胨、2.5g/L K2HPO4、5g/L NaCl、2.5g/L葡萄糖,pH=7.3)中,在30℃和200rpm条件下培养48小时,取样冷冻保藏并转接至G1固体培养基斜面;(剩余部分按10%的接种量转接至含有50mL生产培养基(所述生产培养基为:10g/L可溶性淀粉、5g/L棉籽粉、2g/L CaCO3、0.1g/LCuSO4、0.005g/L NaI,并添加0.5g(1%质量体积比,所有实施例中树脂的用量均为质量(g)体积(mL)比)HP20大孔吸附树脂)的250mL三角烧瓶中,在30℃和200rpm条件下培养7-10天。发酵结束后收集大孔树脂,甲醇浸泡并超声洗脱后将洗脱液合并浓缩至2mL,通过HPLC分析计算突变株的TNM-A产量,最终从34株潜在高产菌株中筛选出G-60-10(简称:CB03234-G)突变菌,其TNM-A产量达到3.7mg/L左右(表3)。
表3.部分潜在TNM-A高产菌株的发酵产量
菌株 | 产量(mg/L) | 菌株 | 产量(mg/L) |
G-60-3 | 1.4±0.3 | G-80-6 | 2.8±0.3 |
G-60-7 | 2.6±0.5 | G-80-7 | 3.1±0.4 |
G-60-10 | 3.7±0.2 | G-80-14 | 2.2±0.3 |
G-60-14 | 1.9±0.3 | CB03234 | 0.8±0.1 |
实施例5:基于CB03234-S和CB03234-G的基因组重排
以TNM-A高产菌株CB03234-S和CB03234-G为亲本,分别制备其对应的高质量原生质体,主要流程如下:(1)取0.2mL过滤的孢子悬液接种到50mL种子培养基(加3g细玻璃珠和0.1%的甘氨酸)中,在30℃恒温摇床200rpm条件下培养36-40小时;(2)离心收集菌丝体后,加入15mL P-buffer(所述P-buffer缓冲液为:103g/L蔗糖、0.25g/L K2SO4、2g/L MgCl2·6H2O,3.7g/L CaCl2·2H2O,0.05g/L KH2PO4)用枪头反复吸打,使菌丝体松散,重复清洗3次;(3)每0.5g菌丝体用5mL P-buffer悬浮,并加入100μL蜗牛酶和50μL溶菌酶(均为10mg/mL,P-buffer配制),轻微混合均匀后在32℃恒温摇床100rpm条件下酶解3小时;(4)再次加入10mL P-buffer,缓慢吸打,用灭菌过滤漏斗(四层擦镜纸制成)过滤掉菌丝体后,低速离心(1000rpm)收集原生质体,并用10mL P-buffer进行清洗,重复2次;(5)最终用5mL P-buffer重新悬浮原生质体,分装成500μL/管(107-108/mL)。将制备好的两个亲本的原生质体悬浮液等体积混合(各500μL),低速离心后弃去上清液,加入5mL 50%PEG-1000融合缓冲液悬浮均匀,37℃恒温水浴静置10min(每3分钟轻柔混合一次)进行融合;随后立即加入5mL P-buffer清洗,并用5mL P-buffer重新悬浮融合的原生质体,并进行适当稀释后涂布于含有50mg/L链霉素和50mg/L庆大霉素的再生平板(103g/L蔗糖;10g/L葡萄糖;0.1g/L酸水解酪蛋白;5g/L酵母粉;0.25g/LKH2PO4;10.12g/L MgCl2·6H2O;5.73g/L TES;20g/L琼脂。以100mL体积分装灭菌后,再依次加入单独灭菌组分:1mL 5g/L KH2PO4;0.8mL 367.5g/LCaCl2·2H2O;0.7mL 1M NaOH)上,在30℃培养箱中培养7-10天,挑选单菌落进行后续筛选。
实施例6:TNM-A高产菌株CB03234-GS26的筛选及验证
将抑菌圈大于原始菌株CB03234的突变单菌落,转接至50mL含有对应浓度链霉素和庆大霉素的胰蛋白胨大豆肉汤(TSB)种子培养基(所述TSB种子培养基为:17g/L胰蛋白胨、3g/L植物蛋白胨、2.5g/L K2HPO4、5g/L NaCl、2.5g/L葡萄糖,pH=7.3)中,在30℃和200rpm条件下培养36-48小时。按10%的接种量转接至含有50mL生产培养基(所述生产培养基为:10g/L可溶性淀粉、5g/L棉籽粉、2g/L CaCO3、0.1g/L CuSO4、0.005g/L NaI,并添加0.5g(1%质量体积比,所有实施例中树脂的用量均为质量(g)体积(mL)比)HP20大孔吸附树脂)的250mL三角烧瓶中,在30℃和200rpm条件下培养7-10天。发酵结束后收集大孔树脂,甲醇浸泡并超声洗脱后将洗脱液合并浓缩至2mL,通过HPLC分析计算突变株的TNM-A产量,最终从26株融合突变菌中筛选出CB03234-GS26,其TNM-A产量达到16mg/L左右(表4),比原有的TNM-A高产菌CB03234-S的产量提高了近2.5倍。
表4.部分GS融合突变菌的TNM-A发酵产量
随后的稳定性试验表明,原始生产培养基条件下CB03234-GS26连续四代的TNM-A产量都在16mg/L左右(表5),具有良好的遗传稳定性。
表5.CB03234-GS26的遗传稳定性验证
孢子代数 | 第一代 | 第二代 | 第三代 | 第四代 |
产量(mg/L) | 16.1±0.3 | 16.0±0.2 | 16.2±1.8 | 16.7±2.3 |
此外,CB03234-GS26在优化培养基(所述优化培养基为:40g/L可溶性淀粉,20g/L棉籽粉,0.1g/L CuSO4·5H2O,0.005g/L NaI和2g/L CaCO3(pH 7.0))中的TNM-A产量进一步提升至38.7±0.2mg/L,与原始菌CB03234约0.8mg/L的产量相比,提高了约48倍。
实施例7:CB03234-GS26的遗传变异分析
提取CB03234-GS26的总DNA进行基因组重测序,并将测序结果与CB03234的参考基因组序列进行对比来寻找基因差异。
表6.CB03234-GS26的遗传变异分析
结果表明,CB03234-GS26中共检测到230个单核苷酸多态性突变(SNP),其中非同义突变96处,导致75个基因编码的蛋白发生了氨基酸序列改变(表6);检测到3处基因编码区域缺失、2处开放读码框移码突变,导致4个基因编码的蛋白发生了氨基酸序列改变(表6),而这些突变均匀分布在CB03234-GS26的全基因组中。此外,CB03234-GS26的基因组结构也发生了明显变异,多处的DNA片段发生了缺失、倒置和异位等变化。上述结果表明基因组重排高产菌CB03234-GS26与原始菌CB03234存在显著的遗传差异。
Claims (3)
1.一株基因组重排高产菌,其特征在于,所述基因组重排高产菌为Streptomycessp.CB03234-GS26,已于2018年7月16日保藏在中国典型培养物保藏中心,保藏编号为CCTCCM 2018485。
2.权利要求1所述的基因组重排高产菌在制备天赐霉素-A及其衍生物中的应用,所述天赐霉素的结构式为:
3.如权利要求2所述的应用,其特征在于,利用权利要求1所述的基因组重排高产菌进行发酵制备天赐霉素-A,发酵过程中使用的培养基的组成如下:40g/L可溶性淀粉,20g/L棉籽粉,0.1g/L CuSO4·5H2O,0.005g/L NaI和2g/L CaCO3,培养基的pH为7.0,并在每升培养基中添加10g HP20大孔吸附树脂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811453409.3A CN110066744B (zh) | 2018-11-30 | 2018-11-30 | 一株基因组重排高产菌及其在生产天赐霉素中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811453409.3A CN110066744B (zh) | 2018-11-30 | 2018-11-30 | 一株基因组重排高产菌及其在生产天赐霉素中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110066744A true CN110066744A (zh) | 2019-07-30 |
CN110066744B CN110066744B (zh) | 2023-01-06 |
Family
ID=67365840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811453409.3A Active CN110066744B (zh) | 2018-11-30 | 2018-11-30 | 一株基因组重排高产菌及其在生产天赐霉素中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110066744B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101974464A (zh) * | 2010-10-18 | 2011-02-16 | 中国科学院南海海洋研究所 | 一种链霉菌及利用该菌发酵制备抗霉素类抗生素的工艺 |
WO2015093839A1 (ko) * | 2013-12-18 | 2015-06-25 | 동국제약 주식회사 | 신규한 스트렙토마이세스 필라멘토서스 변이주 및 이를 이용한 답토마이신의 생산 방법 |
WO2016155568A1 (zh) * | 2015-03-27 | 2016-10-06 | 浙江海正药业股份有限公司 | 一种链霉菌及其生产米尔贝霉素a3的方法 |
-
2018
- 2018-11-30 CN CN201811453409.3A patent/CN110066744B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101974464A (zh) * | 2010-10-18 | 2011-02-16 | 中国科学院南海海洋研究所 | 一种链霉菌及利用该菌发酵制备抗霉素类抗生素的工艺 |
WO2015093839A1 (ko) * | 2013-12-18 | 2015-06-25 | 동국제약 주식회사 | 신규한 스트렙토마이세스 필라멘토서스 변이주 및 이를 이용한 답토마이신의 생산 방법 |
WO2016155568A1 (zh) * | 2015-03-27 | 2016-10-06 | 浙江海正药业股份有限公司 | 一种链霉菌及其生产米尔贝霉素a3的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN110066744B (zh) | 2023-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112029696B (zh) | 一种大菱鲆来源的杀鱼爱德华氏菌及其应用 | |
CN109735467A (zh) | 一种高产他克莫司的链霉菌诱变菌株及其应用 | |
CN107299105A (zh) | 西瓜枯萎病菌致病性FonAGL3基因、其缺失DNA片段、缺失突变体及其应用 | |
CN101402929A (zh) | 一株耐碱纤维堆囊菌及其在制备埃博霉素中的应用 | |
CN116606848A (zh) | 一种灵芝菌株的高通量选育方法 | |
CN103820369B (zh) | 一种萤光假单胞菌及其应用 | |
CN104745654B (zh) | 一种制备尼莫克汀的方法及其生产菌株 | |
CN111778172B (zh) | 一种生产抗菌活性化合物的链霉菌及其分离方法和应用 | |
CN110066744A (zh) | 一株基因组重排高产菌及其在生产天赐霉素中的应用 | |
CN105002106B (zh) | 平板霉素和平板素的高产工程菌株及其发酵和分离纯化工艺 | |
CN108823110A (zh) | 一株产灰黄霉素的菌株及其应用 | |
CN105219657B (zh) | 云芝液体发酵高产多糖菌株及其选育方法 | |
CN101608209B (zh) | 核糖体抗性诱变选育万古霉素生产菌株及其应用 | |
CN103740614A (zh) | 一株高产雷帕霉素的游动放线菌诱变菌株 | |
CN109468253B (zh) | 一种高产雷帕霉素的吸水链霉菌 | |
CN109836431A (zh) | 一种链霉菌发酵产物天赐霉素-a及其衍生物的分离纯化工艺 | |
CN113337432B (zh) | 一种产吡咯喹啉醌的食甲基菌及其应用 | |
CN112409372B (zh) | 玉红霉素类似物、制备方法及其应用 | |
CN1511943A (zh) | 工程菌株及其制备方法以及用其制备紫杉醇的方法 | |
CN105733979B (zh) | 博来霉素衍生物6’-脱羟基-blm s的高产菌株 | |
CN112342146B (zh) | 一种利用l-苯丙氨酸生物发酵合成2-苯乙醇的香灰菌株 | |
CN109306331A (zh) | 一株产抗癌活性物质的公牛链霉菌菌株筛选方法和鉴定方法 | |
CN103820332A (zh) | 蛇足石杉内生真菌及其产石杉碱甲的方法和应用 | |
CN110092758B (zh) | 一种新型生物碱化合物及发酵制备该化合物的疣孢菌株 | |
CN102453708A (zh) | 一种提高天蓝淡红链霉菌柔红霉素产量的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |